Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025

Reuters

08/02

Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025

Exicure Inc. has announced the completion of the last patient, last visit in its Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study, which is assessing the ability of GPC-100, a CXCR4 antagonist, to enhance CD34+ hematopoietic stem cell mobilization, is being conducted in combination with propranolol and G-CSF. Topline results from this randomized, open-label, multicenter study are expected in the fourth quarter of 2025. The company is also exploring the use of GPC-100 in other therapeutic areas, including a planned Phase 1 study in acute myeloid leukemia patients and potential collaborations for its application in cell and gene therapy settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801325070) on August 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556504845"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556504845\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556504845?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-02 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556504845","market":"fut","top_or_hot":-1,"title":"Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exicure Inc. has announced the completion of the last patient, last visit in its Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study, which is assessing the ability of GPC-100, a CXCR4 antagonist, to enhance CD34+ hematopoietic stem cell mobilization, is being conducted in combination with propranolol and G-CSF. Topline results from this randomized, open-label, multicenter study are expected in the fourth quarter of 2025. The company is also exploring the use of GPC-100 in other therapeutic areas, including a planned Phase 1 study in acute myeloid leukemia patients and potential collaborations for its application in cell and gene therapy settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801325070) on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-02 04:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exicure Inc. has announced the completion of the last patient, last visit in its Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study, which is assessing the ability of GPC-100, a CXCR4 antagonist, to enhance CD34+ hematopoietic stem cell mobilization, is being conducted in combination with propranolol and G-CSF. Topline results from this randomized, open-label, multicenter study are expected in the fourth quarter of 2025. The company is also exploring the use of GPC-100 in other therapeutic areas, including a planned Phase 1 study in acute myeloid leukemia patients and potential collaborations for its application in cell and gene therapy settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801325070) on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL2G4Nyg:1","article_id":"2556504845","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556504845","pubTimestamp":1754078473,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire  on August 01, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XCUR":"Exicure, Inc."},"translate_title":"Exicure Inc.完成GPC-100增强多发性骨髓瘤患者干细胞动员的2期研究，预计2025年底取得主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XCUR":0.9},"content_text":"Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025\n    \n\n        Exicure Inc. has announced the completion of the last patient, last visit in its Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study, which is assessing the ability of GPC-100, a CXCR4 antagonist, to enhance CD34+ hematopoietic stem cell mobilization, is being conducted in combination with propranolol and G-CSF. Topline results from this randomized, open-label, multicenter study are expected in the fourth quarter of 2025. The company is also exploring the use of GPC-100 in other therapeutic areas, including a planned Phase 1 study in acute myeloid leukemia patients and potential collaborations for its application in cell and gene therapy settings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801325070) on August 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}